132 related articles for article (PubMed ID: 34638300)
1. Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis.
Espejo-Freire AP; Elliott A; Rosenberg A; Costa PA; Barreto-Coelho P; Jonczak E; D'Amato G; Subhawong T; Arshad J; Diaz-Perez JA; Korn WM; Oberley MJ; Magee D; Dizon D; von Mehren M; Khushman MM; Hussein AM; Leu K; Trent JC
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638300
[TBL] [Abstract][Full Text] [Related]
2. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
[TBL] [Abstract][Full Text] [Related]
4. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
5. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
6. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Durán M; Faull I; Lastra E; Laes JF; Rodrigo AB; Sánchez-Escribano R
J Med Case Rep; 2021 Feb; 15(1):89. PubMed ID: 33608032
[TBL] [Abstract][Full Text] [Related]
7. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
[TBL] [Abstract][Full Text] [Related]
8. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
Gatalica Z; Xiu J; Swensen J; Vranic S
Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy.
Bao X; Zhang H; Wu W; Cheng S; Dai X; Zhu X; Fu Q; Tong Z; Liu L; Zheng Y; Zhao P; Fang W; Liu F
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028695
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score.
Cho YA; Lee H; Kim DG; Kim H; Ha SY; Choi YL; Jang KT; Kim KM
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572886
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy.
Wang S; Fang Y; Jiang N; Xing S; Li Q; Chen R; Yi X; Zhang Z; Li N
Front Immunol; 2021; 12():631483. PubMed ID: 33732253
[TBL] [Abstract][Full Text] [Related]
15. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
16. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR; Connelly CF; Fabrizio D; Gay L; Ali SM; Ennis R; Schrock A; Campbell B; Shlien A; Chmielecki J; Huang F; He Y; Sun J; Tabori U; Kennedy M; Lieber DS; Roels S; White J; Otto GA; Ross JS; Garraway L; Miller VA; Stephens PJ; Frampton GM
Genome Med; 2017 Apr; 9(1):34. PubMed ID: 28420421
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
[TBL] [Abstract][Full Text] [Related]
18. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
[TBL] [Abstract][Full Text] [Related]
19. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.
Painter CA; Jain E; Tomson BN; Dunphy M; Stoddard RE; Thomas BS; Damon AL; Shah S; Kim D; Gómez Tejeda Zañudo J; Hornick JL; Chen YL; Merriam P; Raut CP; Demetri GD; Van Tine BA; Lander ES; Golub TR; Wagle N
Nat Med; 2020 Feb; 26(2):181-187. PubMed ID: 32042194
[TBL] [Abstract][Full Text] [Related]
20. The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients.
Zhou F; Huang Y; Cai W; Li J; Su C; Ren S; Wu C; Zhou C
Lung Cancer; 2021 Mar; 153():66-72. PubMed ID: 33454519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
